Cervix cancer oxygenation measured following external radiation therapy |
| |
| Institution: | 1. Department of Radiation Oncology, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada;2. Department of Experimental Therapeutics, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada;3. Department of Biostatistics, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada;4. Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada;1. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Dresden, Germany;2. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Berlin, Germany;3. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Essen, Germany;4. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Frankfurt, Germany;5. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Freiburg, Germany;6. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Heidelberg, Germany;7. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Munich, Germany;8. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Tübingen, Germany;9. Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;10. OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden – Rossendorf, Germany;11. National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany;12. Department of Oral and Maxillofacial Surgery, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;13. Department of Otorhinolaryngology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;14. Department of Radiooncology and Radiotherapy, Charité University Hospital, Berlin, Germany;15. Department of Radiotherapy, Medical Faculty, University of Duisburg-Essen, Germany;p. Department of Radiotherapy and Oncology, Goethe-University Frankfurt, Germany;q. Department of Radiation Oncology, University of Freiburg, Germany;r. Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany;s. Heidelberg Ion Therapy Center (HIT), Department of Radiation Oncology, University of Heidelberg Medical School, Germany;t. National Center for Tumor Diseases (NCT), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany;u. Translational Radiation Oncology, University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany;v. Clinical Cooperation Unit Radiation Oncology, University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany;w. Department of Radiation Oncology, Ludwig-Maximilians-Universität, Munich, Germany;x. Clinical Cooperation Group, Personalized Radiotherapy in Head and Neck Cancer, Helmholtz Zentrum, Munich, Germany;y. Department of Radiation Oncology, Technische Universität München, Germany;z. Institute of Innovative Radiotherapy (iRT), Helmholtz Zentrum München, Oberschleißheim, Germany;11. Department of Radiation Oncology, Faculty of Medicine and University Hospital Tübingen, Eberhard Karls Universität Tübingen, Germany;12. Medical Systems Biology, University Cancer Center (UCC), University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;13. Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;14. Tumour- and Normal Tissue Bank, University Cancer Center (UCC), University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;15. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA;16. Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark;17. Helmholtz-Zentrum Dresden – Rossendorf, Institute of Radiooncology, Germany;1. Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China;2. The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310053, China;3. Department of Traditional Chinese Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China;1. Universidad de Buenos Aires, Facultad de Agronomía, Cátedra de Botánica General, Buenos Aires, Argentina;2. School of Natural and Environmental Sciences, Agriculture Building, Newcastle University, UK;3. Departamento de Ecologia, Instituto de Biociências, Universidade de São Paulo, Brazil;4. Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina;5. Universidad de Buenos Aires, Facultad de Agronomía, Cátedra de Zoología Agrícola, Buenos Aires, Argentina;6. EAWAG, Center for Ecology, Evolution and Biogeochemistry and Department of Evolutionary Biology and Environmental Studies, University of Zurich, Dubendorf, Switzerland |
| |
| Abstract: | Purpose: Tumor hypoxia may be an important factor predicting relapse following radiation therapy. This study was designed to determine the relationship between the oxygenation parameters measured using a polarographic oxygen electrode, prior to and during treatment in patients with cervix cancer, and to assess these results with regard to patient survival.Materials and Methods: Forty-three patients had pretreatment oxygen assays performed and measurements repeated following external beam radiation to a median dose of 50 Gy (range 26–52 Gy). Stage distribution showed 15 patients in Stage IB, 17 in Stage II, and 11 in Stage III. The median tumor size was 5 cm (range 3–10 cm).Results: The median proportion of pO2 values <5 mm Hg (the HP5) was 41% following radiation, and the median pO2 was 12 mm Hg. These results were not significantly different from the pretreatment HP5 or pO2 of 37% and 12 mm Hg, respectively. Disease-free survival at 2 years was 50% in patients with posttreatment HP5 ≤50%, compared to 60% when posttreatment HP5 was >50% (p = 0.35).Conclusions: Unlike pretreatment results, tumour oxygenation measured following external radiation does not appear to be a useful predictive assay in patients with cervical cancer. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
